Molecular-based Precision Oncology Clinical Decision Making Augmented by Artificial Intelligence

Overview

Journal Emerg Top Life Sci

Specialty Biology

Date 2021 Dec 7

PMID 34874054

Citations 1

Authors

Jia Zeng

Md Abu Shufean

Affiliations

Soon will be listed here.

Abstract

The rapid growth and decreasing cost of Next-generation sequencing (NGS) technologies have made it possible to conduct routine large panel genomic sequencing in many disease settings, especially in the oncology domain. Furthermore, it is now known that optimal disease management of patients depends on individualized cancer treatment guided by comprehensive molecular testing. However, translating results from molecular sequencing reports into actionable clinical insights remains a challenge to most clinicians. In this review, we discuss about some representative systems that leverage artificial intelligence (AI) to facilitate some processes of clinicians' decision making based upon molecular data, focusing on their application in precision oncology. Some limitations and pitfalls of the current application of AI in clinical decision making are also discussed.

Citing Articles

Leveraging Artificial Intelligence to Predict and Manage Complications in Patients With Multimorbidity: A Literature Review.

Chaparala S, Pathak K, Dugyala R, Thomas J, Varakala S Cureus. 2025; 17(1):e77758.

PMID: 39981468 PMC: 11840652. DOI: 10.7759/cureus.77758.

Molecular tumour boards - current and future considerations for precision oncology.

Tsimberidou A, Kahle M, Vo H, Baysal M, Johnson A, Meric-Bernstam F Nat Rev Clin Oncol. 2023; 20(12):843-863.

PMID: 37845306 DOI: 10.1038/s41571-023-00824-4.

References

Lever J, Jones M, Danos A, Krysiak K, Bonakdar M, Grewal J . Text-mining clinically relevant cancer biomarkers for curation into the CIViC database. Genome Med. 2019; 11(1):78. PMC: 6891984. DOI: 10.1186/s13073-019-0686-y. View

Dietlein F, Weghorn D, Taylor-Weiner A, Richters A, Reardon B, Liu D . Identification of cancer driver genes based on nucleotide context. Nat Genet. 2020; 52(2):208-218. PMC: 7031046. DOI: 10.1038/s41588-019-0572-y. View

Leaman R, Gonzalez G . BANNER: an executable survey of advances in biomedical named entity recognition. Pac Symp Biocomput. 2008; :652-63. View

Gonzalez-Perez A, Deu-Pons J, Lopez-Bigas N . Improving the prediction of the functional impact of cancer mutations by baseline tolerance transformation. Genome Med. 2012; 4(11):89. PMC: 4064314. DOI: 10.1186/gm390. View

Ng P, Li J, Jeong K, Shao S, Chen H, Tsang Y . Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell. 2018; 33(3):450-462.e10. PMC: 5926201. DOI: 10.1016/j.ccell.2018.01.021. View

Kalari K, Sinnwell J, Thompson K, Tang X, Carlson E, Yu J . PANOPLY: Omics-Guided Drug Prioritization Method Tailored to an Individual Patient. JCO Clin Cancer Inform. 2019; 2:1-11. PMC: 7010444. DOI: 10.1200/CCI.18.00012. View

Faes L, Liu X, Wagner S, Fu D, Balaskas K, Sim D . A Clinician's Guide to Artificial Intelligence: How to Critically Appraise Machine Learning Studies. Transl Vis Sci Technol. 2020; 9(2):7. PMC: 7346877. DOI: 10.1167/tvst.9.2.7. View

Bailey M, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A . Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell. 2018; 174(4):1034-1035. PMC: 8045146. DOI: 10.1016/j.cell.2018.07.034. View

Jain N, Mittendorf K, Holt M, LeNoue-Newton M, Maurer I, Miller C . The My Cancer Genome clinical trial data model and trial curation workflow. J Am Med Inform Assoc. 2020; 27(7):1057-1066. PMC: 7647323. DOI: 10.1093/jamia/ocaa066. View

10.

Reva B, Antipin Y, Sander C . Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res. 2011; 39(17):e118. PMC: 3177186. DOI: 10.1093/nar/gkr407. View

11.

Martinez-Jimenez F, Muinos F, Sentis I, Deu-Pons J, Reyes-Salazar I, Arnedo-Pac C . A compendium of mutational cancer driver genes. Nat Rev Cancer. 2020; 20(10):555-572. DOI: 10.1038/s41568-020-0290-x. View

12.

Yuan C, Ryan P, Ta C, Guo Y, Li Z, Hardin J . Criteria2Query: a natural language interface to clinical databases for cohort definition. J Am Med Inform Assoc. 2019; 26(4):294-305. PMC: 6402359. DOI: 10.1093/jamia/ocy178. View

13.

Kumar P, Henikoff S, Ng P . Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009; 4(7):1073-81. DOI: 10.1038/nprot.2009.86. View

14.

Kang T, Zhang S, Tang Y, Hruby G, Rusanov A, Elhadad N . EliIE: An open-source information extraction system for clinical trial eligibility criteria. J Am Med Inform Assoc. 2017; 24(6):1062-1071. PMC: 6259668. DOI: 10.1093/jamia/ocx019. View

15.

Hart S, Polley E, Shimelis H, Yadav S, Couch F . Prediction of the functional impact of missense variants in BRCA1 and BRCA2 with BRCA-ML. NPJ Breast Cancer. 2020; 6:13. PMC: 7190647. DOI: 10.1038/s41523-020-0159-x. View

16.

Zeng J, Johnson A, Shufean M, Kahle M, Yang D, Woodman S . Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology. JCO Clin Cancer Inform. 2019; 3:1-12. PMC: 6874004. DOI: 10.1200/CCI.19.00089. View

17.

Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

18.

Mao Y, Chen H, Liang H, Meric-Bernstam F, Mills G, Chen K . CanDrA: cancer-specific driver missense mutation annotation with optimized features. PLoS One. 2013; 8(10):e77945. PMC: 3813554. DOI: 10.1371/journal.pone.0077945. View

19.

Carter H, Douville C, Stenson P, Cooper D, Karchin R . Identifying Mendelian disease genes with the variant effect scoring tool. BMC Genomics. 2013; 14 Suppl 3:S3. PMC: 3665549. DOI: 10.1186/1471-2164-14-S3-S3. View

20.

Miron L, Goncalves R, Musen M . Obstacles to the reuse of study metadata in ClinicalTrials.gov. Sci Data. 2020; 7(1):443. PMC: 7749162. DOI: 10.1038/s41597-020-00780-z. View